Epothilone B induces glioblastoma cell death via survivin down-regulation

Experimental Oncology

Volumn 30, Issue 3, 2008, Pages 195-201

  Quick, Q A ^a  

^a GRAMBLING STATE UNIVERSITY   (United States)

Author keywords

Epothilone B; Glioblastoma; p53; Survivin

Indexed keywords

EPOTHILONE B; PROTEIN P53; SURVIVIN; TUBULIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CELL TYPE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; PROTEIN LOCALIZATION;

APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL PROLIFERATION; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPOTHILONES; FLUORESCENT ANTIBODY TECHNIQUE; GENTIAN VIOLET; GLIOBLASTOMA; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MUTATION; NEOPLASM PROTEINS; TUBULIN; TUBULIN MODULATORS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 53649106685     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Mollinedo F, Gajate C, Micortubles. microtubuleinterfering agents and apoptosis. Apoptosis 2003;8: 413-50.
2. Zhou J, Giannakakou P, Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005;5:65-71.
3. Fojo AT, Menefee M, Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005;32 (6 Suppl 7): S3-8.
4. Nicolaou KC, Ritzén A, Namoto K, Recent developments in the chemistry, biology and medicine of the epothilones. Chem Commun (Camb) 2001;17: 1523-35.
5. Yamaguchi H, Paranawithana SR, Lee MW, et al. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res 2002: 62: 466-71.
6. Sepp-Lorenzino L, Balog A, Su DS, et al. The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells. Prostate Cancer Prostatic Dis. 1999;2:41-52.
7. Uyar D, Takigawa N, Mekhail T, et al. Apoptotic pathways of epothilone BMS 310705. Gynecol Oncol 2003;91: 173-8.
8. Wartmann M, Altmann KH, The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2002;2: 123-48.
9. Ioffe ML, White E, Nelson DA, et al. Epothilone induced cytotoxicity is dependent on p53 status in prostate cells. Prostate 2004;61: 243-7.
10. Griffin D, Wittmann S, Guo F, et al. Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells. Gynecol Oncol 2003;89: 37-47.
11. Vikhanskaya F, Vignati S, Beccaglia P, et al. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp Cell Res 1998;241: 96-101.
12. Bacus SS, Gudkov AV, Lowe M, et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001;20: 147-55.
13. Mooberry SL, Tien G, Hernandez AH, et al. Laulimalide and isolaulimalide, new paclitaxel-like microtubulestabilizing agents. Cancer Res 1999;59: 653-60
14. Dietzmann A, Kanakis D, Kirches E, et al. Nanomolar concentrations of epothilone D inhibit the proliferation of glioma cells and severely affect their tubulin cytoskeleton. J Neurooncol 2003;65: 99-106.
15. Altieri DC, Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 2006;5: 478-82.
16. Chakravarti A, Noll E, Black PM, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002;20: 1063-8.
17. Wang Z, Xie Y, Wang H, Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells. Cancer Biol Ther 2005;4: 716-9.
18. Haroun RI, Clatterbuck RE, Gibbons MC, et al. Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens. J Neurooncol 2002;58: 115-23.
19. Yoshida D, Hoshino S, Shimura T, et al. Drug-induced apoptosis by anti-microtubule agent, estramustine phosphate on human malignant glioma cell line, U87MG; in vitro study. J Neurooncol 2000;47: 133-40.
20. Grzanka A, Grzanka D, Orlikowska M, Cytoskeletal reorganization during process of apoptosis induced by cytostatic drugs in K-562 and HL-60 leukemia cell lines. Biochem Pharmacol 2003;66: 1611-7.
21. Grzanka A, Grzanka D, Orlikkowska M, et al. Estimation of taxol influence on changes in tubulin and vimentin systems in K-562 and HL-60 cell lines by immunofluorescence microscopy. Neoplasma 2005;52: 193-8.
22. Fortugno P, Wall NR, Giodini A, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002;115: 575-85.
23. Blum R, Jacob-Hirsch J, Rechavi G, Kloog Y, Suppression of survivin expression in glioblastoma cells by the Ras inhibitor famesylthiosalicylic acid promotes caspase-dependent apoptosis. Mol Cancer Ther 2006;5: 2337-47.
24. McLaughlin N, Annabi B, Bouzeghrane M, et al. The Survivin-mediated radioresistant phenotype of glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol (-)-epigallocatechin-3-gallate. Brain Res 2006;1071: 1-9.
25. O'Connor DS, Wall XR, Porter AC, Altieri DC, A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2002: 2:43-54.
26. Dohi T, Beltrami E, Wall NR, et al. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004;114: 1117-27.
27. Li D, Cui Q, Chen SG, et al. Inactivation of ras and changes of mitochondrial membrane potential contribute to oridonin-induced autophagy in A431 cells. J Pharmacol Sci 2007;105: 22-33.
28. Gozuacik D, Kimchi A, Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004;23: 2891-906.
29. Cui Q, Tashiro S, Onodera S, et al. Autophagy preceded apoptosis in oridonin-treated human breast cancer MCF-7 cells. Biol Pharm Bull 2007;30: 859-64.
30. González-Polo RA, Boya P, Pauleau AL, et al. The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci 2005;118: 3091-102.
31. Woods CM, Zhu J, McQueney PA, et al. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1995;1: 506-26.
32. Vikhanskaya F, Vignati S, Beccaglia P, et al. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp Cell Res 1998;241:96-101.
33. Nozaki M, Tada M, Kobayashi H, et al. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro Oncol 1999;1: 124-37.
34. Ohgaki H, Kleihues P, Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170: 1445-53.
35. Sah NK, Khan Z, Khan GJ, Bisen PS, Structural, functional and therapeutic biology of survivin. Cancer Lett 2006;244: 164-71.